对比增强超声辅助经皮肾造瘘术:提高无扩张肾集合系统患者成功率的技术
单中心回顾性研究纳入47例(48个肾)无扩张肾集合系统患者,行对比增强超声辅助经皮肾造瘘术,经穿刺针及引流管注入超声造影剂确认造瘘成功。技术成功率按患者及按肾均为100%,无严重并发症,仅4例(8.5%)出现轻微并发症。作者认为该技术有价值且技术成功率高。
要点
- 无扩张肾集合系统行对比增强超声辅助经皮肾造瘘术的技术成功率按患者和按肾均为100%。
- 平均穿刺针次数1.4次,平均手术时间18.9分钟,平均造影剂剂量12.9 mL。
- 无严重并发症,仅4例(8.5%)出现轻微并发症(1例肾周血肿、3例短暂肉眼血尿)。
核心结论
- 对比增强超声辅助经皮肾造瘘术用于无扩张肾集合系统患者具有较高技术成功率,作者认为该技术有价值。
研究设计与样本
- 单中心回顾性研究,纳入2011年11月至2015年9月47例患者(48个肾),平均年龄51.9岁±16.2(范围18-80岁),经穿刺针及引流管注入超声造影剂确认造瘘成功。
关键影像表现/征象
- 经穿刺针及引流管注入超声造影剂可确认经皮肾造瘘成功。
- 术后9天超声发现1例肾周血肿。
- 3例出现持续1-2天的短暂肉眼血尿。
诊断标准与关键数值
- 技术成功率按患者为100%(47/47,95%CI:93.8%,100%),按肾为100%(48/48,95%CI:94.0%,100%)。
- 每个肾平均穿刺针次数为1.4±0.5次(范围1-3次)。
- 平均完整手术时间为18.9分钟±4.8(范围8-30分钟)。
- 平均造影剂剂量为12.9 mL±3.2(范围8-25 mL)。
- 轻微并发症发生率为8.5%(4/47,95%CI:2.37%,20.4%)。
临床应用与阅片要点
- 对无扩张肾集合系统患者,可经穿刺针及引流管注入超声造影剂确认经皮肾造瘘是否成功。
- 术后随访1-30天(平均18.4天±10.3)需观察肾周血肿和肉眼血尿等轻微并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To perform a single-center study of contrast material-enhanced ultrasonography (US)-assisted percutaneous nephrostomy (PCN) for patients with nondilated renal collecting system. Materials and Methods An international review board approved this retrospective study with waiver of informed consent for participation, and the study was approved by the Ethical Committee. From November 2011 to September 2015, 47 patients (mean age, 51.9 years ± 16.2 [standard deviation]; range, 18-80 years) with clinical necessity of urinary drainage, urinary diversion, or provision of access to the collecting system and with nondilated renal collecting system who underwent contrast-enhanced US-assisted PCN for 48 kidneys were included. US contrast agent was injected through the puncture needle and the drainage catheter to confirm successful PCN. The technical success rate and complications were evaluated. Relative frequencies with 95% confidence intervals (CIs) were calculated. Results The technical success rate was 100% (47 of 47, 95% CI: 93.8%, 100%) per patient and 100% (48 of 48, 95% CI: 94.0%, 100%) per kidney. For each kidney, the mean number of needle passes was 1.4 ± 0.5 (range, 1-3). The mean duration of the complete procedure was 18.9 minutes ± 4.8 (range, 8-30 minutes). The mean dose of contrast agent was 12.9 mL ± 3.2 (range, 8-25 mL). No major complications were observed. After a follow-up of 1-30 days (mean, 18.4 days ± 10.3), only four patients (four of 47, 8.5%, 95% CI: 2.37%, 20.4%) had minor complications, including one perirenal hematoma seen at US 9 days after the procedure and three patients with transient macroscopic hematuria that lasted 1-2 days. Conclusion Contrast-enhanced US-assisted PCN in patients with nondilated renal collecting system is valuable with high technical success rate. © RSNA, 2017.
引用
- Liu BX, Huang GL, Xie XH, et al. Contrast-enhanced US-assisted Percutaneous Nephrostomy: A Technique to Increase Success Rate for Patients with Nondilated Renal Collecting System. Radiology. 2017. PMID: 28467143. doi:10.1148/radiol.2017161604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。